LANDscape MApping of Epitopes and T Cell Receptors for Selected Cancers
Recruiting now NCT04665388
Run by University Health Network, Toronto · for 18 and older · All sexes
What this study is about
This is a correlative research project aimed at characterizing the T cell mediated immune responses to hepatocellular carcinoma (HCC), as well as Epstein-Barr virus (EBV)- and human papillomavirus (HPV)-related cancers. This study will enroll approximately 105 patients over 48 months. Of these 105 patients, 30 are EBV-related cancer, 45 are HPV-related cancer, and 30 are HCC. Patients will have blood samples collected one time to identify cancer specific T cells and T cell receptors in their blood. They will also have tissue samples collected one time to study the different types of immune cells, especially the T cells and their receptors. The 105 patients enrolled in this study will be compared to retrospective samples (N=210; 30 from EBV-related cancer cohort, 180 from HPV-related cancer cohort).
Who can join (things the study team will check)
✅ You may be able to join if…
- Patients with a histological or cytological diagnosis of:
- EBV-related malignancies (e.g. nasopharyngeal cancer)
- HPV-related malignancies, including squamous cell carcinoma of the head and neck, cervix, vulva or anal canal. HPV positivity is required for squamous cell cancers of the head and neck.; p16 positivity as a surrogate for HPV testing is acceptable. HPV positivity is not required for cervix, vulva or anal canal cancer.
- For cancers of the anal canal, late stage distant metastatic tumor tissue is preferred. However, early stage primary site tissue is acceptable, if the tissue can be procured without contamination by intestinal microbiota.
- For HCC, only patients who have above UHN institutional upper limit of normal levels of alpha-fetoprotein (AFP) in serum will be eligible. The diagnosis of HCC should be made based on standard of care with or without tumor tissue confirmation.
- Patients must be ≥ 18 years old.
- Patients must have provided voluntary written informed consent.
🚫 You may not be able to join if…
- Any condition that, in the opinion of the Investigator, would interfere with patient safety, or evaluation of the collected specimens and interpretation of study results.
Where this trial is running
- Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Who to contact
Kathy Han, MD · 416-946-4501 · tip@uhn.ca
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT04665388.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.